Quotient Clinical Builds a U.S. CRO Presence

by | Feb 15, 2017 9:46 pm | CRO, Other Services | 0 comments

The clinical research (CRO) market in the United States has attracted the interest of foreign investors looking to build up their platforms overseas. Quotient Clinical, a privately-held CRO based in Edinburgh, Scotland, acquired two U.S.-based CROs in February 2017, in an effort to bring its innovative Translational Pharmaceutics ® platform to America. But this CRO had to change a few hands over the past few years before it could reach acquirer status. In December 2013, the U.K.-based Quotient Bioresearch Group sold Quotient Clinical to London-based Bridgepoint Development Capital, marking Bridgepoint’s entry into a growing CRO market. Just two years later, in December 2015,... Read More »

Charles River Buys WIL Research

by | Jan 7, 2016 8:51 pm | Laboratories, MRI & Dialysis | 0 comments

Charles River Laboratories International, Inc. (NYSE CRL) started the year off with the acquisition of WIL Research, which provides safety assessment, contract development and manufacturing (CDMO) services to biopharmaceutical, agricultural and industrial chemical companies worldwide. The purchase price was approximately $585 million in cash. WIL Research will join Celsis International Ltd., acquired in July 2015 for $212 million, in Charles River’s growing global business. Celsis provides rapid bacterial detection systems for quality control testing in the biopharmaceutical and consumer products industries. This acquisition will grow its global presence, especially in Europe. It will also... Read More »